You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 20, 2024

~ Buy the CIPRODEX (ciprofloxacin; dexamethasone) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR CIPRODEX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ciprodex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00945802 ↗ FST-201 In The Treatment of Acute Otitis Externa Terminated Shire Phase 3 2009-07-31 The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute otitis externa.
NCT00956748 ↗ N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Withdrawn St. Paul's Hospital, Canada Phase 4 2019-11-29 Chronic suppurative otitis media (CSOM) can be particularly difficult to treat as a number of patients do not respond to routine antibiotic or surgical treatments. The current treatment involves administering combination antibiotic anti-inflammatory ear drops such as Ciprodex (ciprofloxacin 0.3% / dexamethasone 0.1%). Although most patients experience a relief of symptoms, a fraction of patients remain refractory to treatment. Recent findings suggest that the addition of N-acetylcysteine (0.5-2%) to Ciprodex is a superior treatment for otitis media with effusion compared to the use of Ciprodex alone.
NCT00961675 ↗ FST-201 in the Treatment of Acute Otitis Externa Completed Shire Phase 3 2009-08-31 The objective of this study is to evaluate the efficacy of FST-201 compared to Ciprodex in the treatment of acute otitis externa. This study will be conducted at one site, the Lyndon B. Johnson (LBJ) Tropical Medical Center, Department of Otolaryngology, in Pago Pago, American Samoa.
NCT01027494 ↗ Topical Treatment of Acute Otitis Media Through Tympanostomy Tubes (AOMT) and Its Effect on Microbial Flora Completed Alcon Research 2009-12-01 The purpose of this observational study was to evaluate the effects of a topical fluoroquinolone (antibiotic) instilled into the otic (ear) canal to treat Acute Otitis Media through Tympanostomy Tubes (AOMT) on selected bacterial species on the skin near the ear, in the nose, and in the throat.
NCT01359098 ↗ Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa Completed Otic Pharma Phase 2 2011-07-01 The purpose of this study is to assess the Safety and Efficacy of Ciprodexa Foam (0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam), used once-a-day for 7 days for the treatment of Acute Diffuse Otitis Externa, compared to Ciprodex otic suspension used twice daily for 7 days.
NCT01908803 ↗ Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes Terminated Alcon Research Phase 2 2013-12-01 The purpose of this study is to evaluate a single application of AL-60371/AL-817 Otic Suspension relative to ototopical CIPRODEX for sustained clinical cure, microbiological success, and time to cessation of otorrhea.
NCT01910155 ↗ A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa Terminated Novum Pharmaceutical Research Services Phase 3 2013-07-01 The objective of this study is to compare the relative efficacy and safety of the test formulation of ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension (Par Pharmaceutical Companies, Inc.) to the already-marketed formulation CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%) sterile otic suspension (Alcon) in the treatment of acute bacterial otitis externa.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ciprodex

Condition Name

Condition Name for ciprodex
Intervention Trials
Acute Otitis Externa 3
Otorrhea 2
Acute Otitis Media 2
Otitis Externa 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ciprodex
Intervention Trials
Otitis 9
Otitis Media 5
Otitis Externa 5
Ear Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ciprodex

Trials by Country

Trials by Country for ciprodex
Location Trials
United States 51
Puerto Rico 2
American Samoa 1
Canada 1
Israel 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ciprodex
Location Trials
Texas 4
Florida 4
Virginia 3
Oregon 3
Ohio 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ciprodex

Clinical Trial Phase

Clinical Trial Phase for ciprodex
Clinical Trial Phase Trials
Phase 4 2
Phase 3 5
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ciprodex
Clinical Trial Phase Trials
Completed 4
Terminated 4
Withdrawn 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ciprodex

Sponsor Name

Sponsor Name for ciprodex
Sponsor Trials
Alcon Research 2
Novum Pharmaceutical Research Services 2
Par Pharmaceutical, Inc. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ciprodex
Sponsor Trials
Industry 10
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.